Jazz Pharmaceuticals announced updated Ziihera survival data on October 23, 2026, extending median follow-up in its pivotal HERIZON-GEA-01 trial to 35.3 months. The company said the results reinforced the survival benefits of Ziihera-based combinations for adults with HER2-positive advanced gastroesophageal adenocarcinoma.
Key Takeaways
- Jazz presented longer-term Phase 3 survival findings at the European Society for Medical Oncology Congress in Madrid.
- The update follows FDA approval of two Ziihera-containing first-line regimens on August 25, 2026.
- Earlier FDA-reviewed results differed by treatment combination and tumor subgroup, making those distinctions important when assessing the update.
Table of Contents
- Ziihera survival data add longer-term follow-up
- August approval established two different treatment populations
- Earlier results distinguish the two combinations
- Conclusion
Ziihera survival data add longer-term follow-up
HERIZON-GEA-01 evaluates Ziihera with chemotherapy, with or without Tevimbra, as an initial treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma. The October presentation extended observation beyond the initial interim analysis and included three-year landmark survival findings.
Longer follow-up helps assess whether treatment benefits persist over time. However, the available details of the October update do not include revised median overall survival estimates, hazard ratios or three-year survival percentages, limiting a numerical comparison with the earlier analysis.
| Item | Details |
|---|---|
| Earlier overall survival: Ziihera, Tevimbra and chemotherapy | 26.4 months, versus 19.2 months for trastuzumab and chemotherapy in the FDA-reviewed analysis. |
| Earlier progression-free survival: three-drug regimen | 12.4 months, versus 8.1 months for the comparator. |
| Earlier progression-free survival: Ziihera and chemotherapy | 14.2 months in patients with IHC 3+ tumors, versus 7.6 months for the comparator. |
| Trial design | Randomized, three-arm, open-label global study, with patients assigned equally among the treatment groups. |
August approval established two different treatment populations
The FDA’s August approval of Ziihera combinations covered first-line treatment of adults with unresectable locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma. The regimen containing Ziihera, Tevimbra and chemotherapy was approved for HER2-positive tumors classified as IHC 3+ or IHC 2+/ISH+ using an FDA-approved test.
Ziihera plus chemotherapy without Tevimbra received a narrower approval for patients with IHC 3+ tumors. These laboratory classifications determine which patients fall within each approved indication; the two regimens do not have identical eligible populations.
The FDA decision preceded the October presentation. Its efficacy figures therefore provide an earlier benchmark, not verification of the newly announced 35.3-month follow-up.
Earlier results distinguish the two combinations
In the earlier FDA-reviewed analysis, Ziihera with Tevimbra and chemotherapy significantly improved overall survival and progression-free survival versus trastuzumab with chemotherapy. Ziihera with chemotherapy alone significantly improved progression-free survival, but its interim overall survival result was not statistically significant at that analysis.
That distinction matters when interpreting Jazz’s broader description of survival benefits across Ziihera-based regimens. The October announcement concerns additional clinical follow-up, not a new regulatory approval, and does not establish a quantified effect on company revenue or earnings.
Conclusion
Ziihera survival data add longer-term clinical evidence following the August approvals. Detailed updated results by regimen and patient subgroup are the key information to assess next; no further presentation or regulatory decision date was specified in the available announcement details.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
